Tumor growth is an active metabolic process requiring a
continuous supply of nutrients and oxygen. This
need is met by attraction of new vasculature. Inhibition of blood vessel
formation is therefore a promising way of cancer treatment.
Figure: A little tumor, 3x4 mm in size and grown in a
preclinical animal model, attracting microvasculature
from the host vascular bed for its growth.
The Angiogenesis Laboratory has a longterm interest in
the relationship between angiogenesis and the immune system. Many
mechanisms of interplay have been discovered. The main observation is that
inhibition of angiogenesis reinforces the anti-tumor immune response. A
double strike would be to induce an immune response to the tumor
Cancer vaccines are beginning to pick up activity as
evidenced by the success of recent proof-of-concept clinical trials.
Vaccination against the tumor vasculature is an underestimated potential
new tool for the treatment of cancer.
We use the highly specific and proprietary targets to
raise an immune response by protein conjugation to potent antigens. This
technology has shown to induce efficient antibody responses, leading to
profound anti-tumor activities.